Literature DB >> 22481632

Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA).

Gemma Sesmilo1, Sonia Gaztambide, Eva Venegas, Antonio Picó, Carlos Del Pozo, Concepción Blanco, Elena Torres, Cristina Álvarez-Escolà, Carmen Fajardo, Rogelio García, Rosa Cámara, Ignacio Bernabeu, Alfonso Soto, Carles Villabona, Alicia Serraclara, Irene Halperin, Victoria Alcázar, Elisabet Palomera, Susan M Webb.   

Abstract

Since 1997 there is an online National Registry of acromegalic patients in Spain (REA). We aimed to study changes in acromegaly treatment and outcomes over the last four decades in Spain. In REA clinical and biochemical data are collected at diagnosis and updated every one to 2 years. We analyzed the first treatment received and the different treatments administered according to decade of diagnosis of acromegaly: prior to 1980, 1980-1989, 1990-1999 and 2000-2009. Surgical cure rates according to pretreatment with long-acting somatostatin receptor ligands (SRLs) were also analyzed. 1,658 patients were included of which 698 had accurate follow-up data. Treatment of acromegaly changed over time. Surgery was the main treatment option (83.8 %) and medical treatment was widely used (74.7 %) both maintained over decades, while radiation therapy declined (62.8, 61.6, 42.2 and 11.9 % over decades, p < 0.001). First treatment type also changed: surgery was the first line option up until the last decade in which medical treatment was preferred (p < 0.001). Radiotherapy was barely used as first treatment. Treatment combinations changed over time (p < 0.001). The most common treatment combination (surgery plus medical therapy), was received by 24.4, 16.4, 25.3 and 56.5 % of patients over decades. Medical treatment alone was performed in 7.3, 6, 7.2 and 14.7 % over decades. Type of medical treatment also changed, SRLs becoming the first medical treatment modality in the last decades, whereas dopamine agonist use declined (p < 0.001). Surgical cure rates improved over decades (21, 21, 36 and 38 %, p = 0.002) and were not influenced by SRL pre-surgical use. Acromegaly treatment has changed in Spain in the last four decades. Surgery has been the main treatment option for decades; however, medical therapy has replaced surgery as first line in the last decade and radiotherapy rates have clearly declined. SRLs are the most used medical treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22481632     DOI: 10.1007/s11102-012-0384-x

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  21 in total

1.  Effect of octreotide pretreatment on surgical outcome in acromegaly.

Authors:  A Colao; D Ferone; P Cappabianca; M L del Basso De Caro; P Marzullo; A Monticelli; A Alfieri; B Merola; A Calì; E de Divitiis; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

2.  Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates.

Authors:  Marco Losa; Pietro Mortini; Laura Urbaz; Paolo Ribotto; Tristana Castrignanó; Massimo Giovanelli
Journal:  J Neurosurg       Date:  2006-06       Impact factor: 5.115

3.  Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.

Authors:  S J Hunter; J A Shaw; K O Lee; P J Wood; A B Atkinson; J S Bevan
Journal:  Clin Endocrinol (Oxf)       Date:  1999-02       Impact factor: 3.478

4.  Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.

Authors:  J Schopohl; C J Strasburger; D Caird; K Badenhoop; F Beuschlein; M Droste; U Plöckinger; S Petersenn
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-11-17       Impact factor: 2.949

5.  Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.

Authors:  Nienke R Biermasz; Niels C van den Oever; Marijke Frölich; Alberto M Pereira Arias; Jan W A Smit; Johannes A Romijn; Ferdinand Roelfsema
Journal:  Clin Endocrinol (Oxf)       Date:  2003-03       Impact factor: 3.478

Review 6.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

Review 7.  [Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry].

Authors:  Ph Jaquet; Ch Cortet-Rudelli; G Sassolas; I Morange-Ramos; P Chanson; Th Brue; J-M Andrieu; A Beckers; J Bertherat; F Borson-Chazot; G Brassier; Ph Caron; M Cogne; J-Ph Cottier; B Delemer; H Dufour; A Enjalbert; D Figarella-Branger; R Gaillard; M Gueydan; M Jan; J-M Kuhn; I Raingeard; J Regis; P Roger; V Rohmer; J-L Sadoul; A Saveanu; A Tabarin; N Travers; J Trouillas
Journal:  Ann Endocrinol (Paris)       Date:  2003-12       Impact factor: 2.478

8.  Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register.

Authors:  S Petersenn; M Buchfelder; M Reincke; C M Strasburger; H Franz; R Lohmann; H-J Quabbe; U Plöckinger
Journal:  Eur J Endocrinol       Date:  2008-08-28       Impact factor: 6.664

9.  One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.

Authors:  Ph Caron; M Bex; D R Cullen; U Feldt-Rasmussen; A M Pico Alfonso; S Pynka; K Racz; J Schopohl; A Tabarin; M J Valimaki
Journal:  Clin Endocrinol (Oxf)       Date:  2004-06       Impact factor: 3.478

10.  Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.

Authors:  T Lucas; R Astorga
Journal:  Clin Endocrinol (Oxf)       Date:  2006-09       Impact factor: 3.478

View more
  13 in total

Review 1.  Updates in outcomes of stereotactic radiation therapy in acromegaly.

Authors:  Monica Livia Gheorghiu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 2.  Expert consensus document: A consensus on the medical treatment of acromegaly.

Authors:  Andrea Giustina; Philippe Chanson; David Kleinberg; Marcello D Bronstein; David R Clemmons; Anne Klibanski; Aart J van der Lely; Christian J Strasburger; Steven W Lamberts; Ken K Y Ho; Felipe F Casanueva; Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2014-02-25       Impact factor: 43.330

3.  Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly.

Authors:  Marco Losa; Jens Bollerslev
Journal:  Endocrine       Date:  2016-01-19       Impact factor: 3.633

4.  Octreotide LAR treatment of acromegaly in "real life": long-term outcome at a tertiary care center.

Authors:  Ana Laura Espinosa-de-los-Monteros; Baldomero Gonzalez; Guadalupe Vargas; Ernesto Sosa; Moises Mercado
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 5.  STEREOTACTIC RADIATION THERAPY IN PITUITARY ADENOMAS, IS IT BETTER THAN CONVENTIONAL RADIATION THERAPY?

Authors:  M L Gheorghiu; M Fleseriu
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Oct-Dec       Impact factor: 0.877

6.  Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective.

Authors:  Federica Nista; Giuliana Corica; Lara Castelletti; Keyvan Khorrami; Claudia Campana; Francesco Cocchiara; Gabriele Zoppoli; Alessandro Prior; Diego Criminelli Rossi; Gianluigi Zona; Diego Ferone; Federico Gatto
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-07       Impact factor: 5.555

7.  Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

Authors:  John D Carmichael; Vivien S Bonert; Miriam Nuño; Diana Ly; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2014-02-25       Impact factor: 5.958

Review 8.  The risks of overlooking the diagnosis of secreting pituitary adenomas.

Authors:  Thierry Brue; Frederic Castinetti
Journal:  Orphanet J Rare Dis       Date:  2016-10-06       Impact factor: 4.123

9.  Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

Authors:  Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers
Journal:  Endocr Relat Cancer       Date:  2017-07-21       Impact factor: 5.678

10.  Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center.

Authors:  John D Carmichael; Michael S Broder; Dasha Cherepanov; Eunice Chang; Adam Mamelak; Qayyim Said; Maureen P Neary; Vivien Bonert
Journal:  BMC Endocr Disord       Date:  2017-08-04       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.